Jia Xiaotian, Chen Chao, Chen Lin, Yu Cong, Kondo Tadashi
Department of Hand Surgery, Huashan Hospital, Fudan University, Shanghai 200040, P.R. China.
Key Laboratory of Hand Reconstruction, Ministry of Health, Shanghai 200040, P.R. China.
Oncol Lett. 2019 Mar;17(3):3517-3522. doi: 10.3892/ol.2019.9959. Epub 2019 Jan 23.
Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive soft-tissue sarcomas. The prognosis of MPNSTs has been reported to differ among previous studies. However, there have been a number of reported prognostic biomarkers associated with MPNSTs. In the present study, a proteomics study was performed to discover the differential protein expression in patients with MPSNTs with different prognoses. The clinical data of 30 primary extremities of patients with MPNSTs, who underwent surgery at the Department of Hand Surgery, Huashan Hospital, Fudan University between January 2002 and December 2011, were acquired. A total of 16 patients succumbed to their diseases within 5 years, whereas 14 patients were disease-free for >5 years. Samples from the 9 patients who succumbed within 2 years were assigned to Group D, while samples from the 8 patients who were continuously disease-free for >5 years following diagnosis were assigned to Group L for the proteomics study. Label-free quantitative proteomics and mass spectrometry were performed to filtrate differential protein in patients with MPSNTs with different prognoses. Decorin was filtrated as a differential protein of note. The expression level of decorin was significantly lower in Group D compared with that in Group L (D/L=0.0948; P=0.0004). The result was verified by immunohistochemical staining in the 30 primary extremities of patients with MPNSTs. The 5-year survival rate of patients with positive expression of decorin was 78.57%, while the 5-year survival rate of patients negative for decorin expression was 18.75% (P=0.0014). Overall, a high level of decorin indicted a better prognosis in patients with MPNSTs. With further investigation, decorin may be a reliable prognostic biomarker for MPNSTs.
恶性外周神经鞘瘤（MPNSTs）是侵袭性软组织肉瘤。据报道，MPNSTs的预后在以往研究中存在差异。然而，已有许多与MPNSTs相关的预后生物标志物被报道。在本研究中，进行了一项蛋白质组学研究，以发现不同预后的MPNSTs患者的差异蛋白表达。收集了2002年1月至2011年12月在复旦大学附属华山医院手外科接受手术的30例MPNSTs患者的30个原发性肢体的临床资料。共有16例患者在5年内死于疾病，而14例患者无病生存超过5年。将2年内死亡的9例患者的样本分配到D组，而将诊断后持续无病生存超过5年的8例患者的样本分配到L组进行蛋白质组学研究。采用无标记定量蛋白质组学和质谱技术筛选不同预后的MPNSTs患者的差异蛋白。核心蛋白聚糖被筛选为值得注意的差异蛋白。D组核心蛋白聚糖的表达水平明显低于L组（D/L = 0.0948；P = 0.0004）。该结果在30例MPNSTs患者的原发性肢体中通过免疫组织化学染色得到验证。核心蛋白聚糖表达阳性患者的5年生存率为78.57%，而核心蛋白聚糖表达阴性患者的5年生存率为18.75%（P = 0.0014）。总体而言，高水平的核心蛋白聚糖表明MPNSTs患者预后较好。随着进一步研究，核心蛋白聚糖可能是MPNSTs可靠的预后生物标志物。
